abemaciclib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Cyclin-dependent kinase 4.
- Target
- Cyclin-dependent kinase 4
- Mechanism
- Cyclin-dependent kinase 6 inhibitor
pharma · Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breast Cancer · Acute Myeloid Leukemia
Stemline Therapeutics (United
Stemline Therapeutics B.V.
Stemline Therapeutics (United drug portfolio — 29 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
New York, USA HQ
767 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- New York, USA
- Employees
- 767
- Programs
- 7
- Drugs
- 29
- Patents
- 0
Stemline Therapeutics (United pipeline
Portfolio lens on 29 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Stemline Therapeutics (United drug portfolio — 29 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Aromatase.
- Target
- Aromatase
- Mechanism
- Cytochrome P450 19A1 inhibitor
-
Development asset linked to Stemline Therapeutics (United in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
elacestrant
Antineoplastic and immunomodulating agents (L02)Antineoplastic and immunomodulating agents (L02) compound in Stemline Therapeutics (United's portfolio. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha degrader
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha degrader
-
Development asset linked to Stemline Therapeutics (United in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
everolimus
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Peptidyl-prolyl cis-trans isomerase FKBP1A.
- Target
- Peptidyl-prolyl cis-trans isomerase FKBP1A
- Mechanism
- FK506-binding protein 1A inhibitor
-
US regulatory status: approved. Molecular target: Aromatase.
- Target
- Aromatase
- Mechanism
- Cytochrome P450 19A1 inhibitor
-
US regulatory status: approved. Molecular target: Lanosterol 14-alpha demethylase.
- Target
- Lanosterol 14-alpha demethylase
- Mechanism
- Cytochrome P450 51 inhibitor
-
US regulatory status: approved. Mechanism: Gonadotropin-releasing hormone receptor agonist.
- Mechanism
- Gonadotropin-releasing hormone receptor agonist
-
Development asset linked to Stemline Therapeutics (United in public FDA and regional records.
-
Development asset linked to Stemline Therapeutics (United in public FDA and regional records.
-
Development asset linked to Stemline Therapeutics (United in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Aromatase.
- Target
- Aromatase
- Mechanism
- Cytochrome P450 19A1 inhibitor
-
Development asset linked to Stemline Therapeutics (United in public FDA and regional records.
-
Development asset linked to Stemline Therapeutics (United in public FDA and regional records.
-
Development asset linked to Stemline Therapeutics (United in public FDA and regional records.
-
Development asset linked to Stemline Therapeutics (United in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Peroxisome proliferator-activated receptor gamma.
- Target
- Peroxisome proliferator-activated receptor gamma
- Mechanism
- Peroxisome proliferator-activated receptor gamma agonist
-
Development asset linked to Stemline Therapeutics (United in public FDA and regional records.
-
Development asset linked to Stemline Therapeutics (United in public FDA and regional records.
-
Development asset linked to Stemline Therapeutics (United in public FDA and regional records.
-
tagraxofusp
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Stemline Therapeutics (United's portfolio. Molecular target: Elongation factor 2.
- Target
- Elongation factor 2
- Mechanism
- Interleukin-3 receptor subunit alpha binding agent
-
Development asset linked to Stemline Therapeutics (United in public FDA and regional records. Mechanism: Estrogen receptor alpha modulator.
- Mechanism
- Estrogen receptor alpha modulator
-
Development asset linked to Stemline Therapeutics (United in public FDA and regional records.
-
Development asset linked to Stemline Therapeutics (United in public FDA and regional records.
-
Development asset linked to Stemline Therapeutics (United in public FDA and regional records. Mechanism: Gonadotropin-releasing hormone receptor agonist.
- Mechanism
- Gonadotropin-releasing hormone receptor agonist